Gyeonggi-do, South Korea

Ki Hwan Chang

This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignee: The Green Cross Corporation. Active years: 2017-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ki Hwan Chang. Retrieved from https://idiyas.com/inventor/ki-hwan-chang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 50.0


 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Gyeonggi-do, KR (2017)
  • Yongin-si, KR (2019)

Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ki Hwan Chang: Innovator in Biotechnology

Introduction

Ki Hwan Chang is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of innovative methods and kits for measuring proteins and antibodies. With a total of 2 patents to his name, Chang's work has the potential to impact the medical field significantly.

Latest Patents

Chang's latest patents include a "Kit for measuring titer of a protein comprising human Fc using indirect ELISA" and a "Method for measuring titer of a protein comprising human Fc using the same." This invention provides a comprehensive kit designed for measuring the titer of human antibodies, humanized antibodies, or human Fc-fusion proteins in human plasma or serum. The kit includes essential components such as a diluent for samples, a diluent for conjugates, and a cleansing solution, facilitating analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA).

Another notable patent is the "Antibody composition for prevention or treatment of mutant hepatitis B virus infection." This invention presents an antibody that binds to the surface antigen (HBsAg) of the hepatitis B virus (HBV), effectively neutralizing the virus. The antibody has been shown to inhibit viral replication, particularly in cases of mutations that occur in the binding site. The efficacy of this antibody was confirmed through studies using patient-derived viruses and in vivo models, demonstrating its potential for treating infections caused by both wild-type and mutant hepatitis B viruses.

Career Highlights

Throughout his career, Ki Hwan Chang has worked with notable organizations such as the Green Cross Corporation and Mogam Biotechnology Research Institute. His experience in these companies has contributed to his expertise in biotechnology and innovation.

Collaborations

Chang has collaborated with esteemed colleagues, including Se-Ho Kim and Kwang-Won Hong, further enhancing his research and development efforts in the field.

Conclusion

Ki Hwan Chang's contributions to biotechnology through his innovative patents and collaborations highlight his role as a significant inventor in the industry. His work not only advances scientific knowledge but also holds promise for practical applications in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…